Source:http://linkedlifedata.com/resource/pubmed/id/12225330
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
2002-9-12
|
| pubmed:abstractText |
High-dose induction with alpha-interferon induces early viral clearance of hepatitis C and combined with ribavirin enhances sustained response. We assess whether adding ribavirin after viral clearance obtained by alpha-interferon induction increased the rate of viral eradication.Forty-one naïve patients with chronic hepatitis C were randomised to receive, after 4 weeks of 10 mU daily of alpha-interferon (induction), 3 mU daily for 22 weeks and 3 mU thrice weekly for 26 weeks of either interferon alone (monotherapy) or interferon plus 1000-1200 mg daily of ribavirin (combination therapy). At the end of the induction phase, 23 (56%) subjects had cleared HCV-RNA. During therapy, breakthrough was observed in four patients on monotherapy, but never in patients on combination therapy. The rate of clearance of HCV-RNA was different between monotherapy and combination therapy at the end of treatment (40% vs. 76.1%, P=0.02) and at the end of follow-up (5% vs. 57.1%, P=0.001). Twelve of the 23 patients who cleared HCV-RNA during induction, but only one of the 18 still HCV-RNA-positive after 4 weeks of therapy, had a sustained response (52.2% vs. 5.6%, P=0.001). Clearance of HCV-RNA at 1 week had a high positive predictive value for sustained response in combination therapy (PPV=0.75), but not in monotherapy (PPV=0.33). Induction with high daily doses of alpha-interferon obtains suppression of hepatitis C in more than half of patients, but ribavirin is needed to maintain a sustained response. The rate of sustained response is a function of the time to HCV-RNA clearance. In patients not responding to induction therapy addition of ribavirin does not obtain a sustained virological response.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Sep
|
| pubmed:issn |
1352-0504
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
9
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
354-9
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:12225330-Adolescent,
pubmed-meshheading:12225330-Adult,
pubmed-meshheading:12225330-Aged,
pubmed-meshheading:12225330-Antiviral Agents,
pubmed-meshheading:12225330-Dose-Response Relationship, Drug,
pubmed-meshheading:12225330-Drug Administration Schedule,
pubmed-meshheading:12225330-Drug Therapy, Combination,
pubmed-meshheading:12225330-Enzyme-Linked Immunosorbent Assay,
pubmed-meshheading:12225330-Female,
pubmed-meshheading:12225330-Hepacivirus,
pubmed-meshheading:12225330-Hepatitis C, Chronic,
pubmed-meshheading:12225330-Humans,
pubmed-meshheading:12225330-Interferon-alpha,
pubmed-meshheading:12225330-Male,
pubmed-meshheading:12225330-Middle Aged,
pubmed-meshheading:12225330-RNA, Viral,
pubmed-meshheading:12225330-Ribavirin,
pubmed-meshheading:12225330-Treatment Outcome,
pubmed-meshheading:12225330-Viremia
|
| pubmed:year |
2002
|
| pubmed:articleTitle |
Early viral clearance and sustained response in chronic hepatitis C: a controlled trial of interferon and ribavirin after high-dose interferon induction.
|
| pubmed:affiliation |
Cattedra di Gastroenterologia, Clinica Medica, University of Palermo, Palermo, Italy. vito.dimarco@tin.it
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|